Company: REVB
Filing Date: 2025-05-23
Form Type: S-1/A
Source: 0001213900-25-047104
Chunk: 80

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-23
Form: S-1/A
Chunk 80
---
 determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the public offering price per share paid by new investors. The following table illustrates this per share dilution:

| Assumed public offering price per share (attributing          
 no value to the warrants)                                     |     | $ | 2.565 |   |
| Net tangible book value per share as of March 31, 2025        |     | $ |  2.99 |   |
| Decrease in pro forma as adjusted net tangible book value     
 per share after this offering                                 |     | $ | (0.51 | ) |
| Pro forma as adjusted net tangible book value per share after 
 giving effect of this offering                                |     | $ |  2.48 |   |
| Dilution in pro forma as adjusted net tangible book value     
 per share to new investors                                    |     | $ | 0.085 |   |

Each $1.00 increase (decrease) in the public offering price of $2.565 per share and accompanying Common Stock Warrants would increase (decrease) the pro forma as adjusted net tangible book value per share by $0.62, and the dilution per share to new investors in this offering by $0.38, assuming the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the Placement Agent fees and commissions and estimated offering expenses payable by us. Each increase of 1,000,000 in the number of shares of common stock and accompanying Common Stock Warrants sold in this offering would increase (decrease) our pro forma as adjusted net tangible book value by approximately $0.81 and the dilution per share to new investors in this offering by $1.755, assuming that the public offering price per share and accompanying Common Stock Warrants remains the same and after deducting Placement Agent fees and commissions and estimated offering expenses payable by us. The above discussion and table is based on 963,796 shares of common stock outstanding on March 31, 2025, and excludes the following:

| ● | 97,880 shares of our common stock reserved for issuance under 
 our 2021 Equity Incentive Plan;                               |

| ● | 3 shares of our common stock reserved for the issuance of 
 Rollover RSUs;                                            |

| ● | 64 shares issuable upon exercise of stock options outstanding 
 under our 2021